CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading organization profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Organizations/education

education organization

University of Verona

IT

OPENALEX: I119439378↗ROR: 039bp8j42↗

People

Connected researchers

Antonio LasalviaORCID 0000-0001-9963-6081 Chiara BonettoORCID 0000-0001-9895-6403 Corrado BarbuiORCID 0000-0003-1073-9282 Domenico BerardiORCID 0000-0002-5694-4567 Doriana CristofaloExact authorship link Fidelia CasciniORCID 0000-0001-6499-0734 Lorenzo ZamboniORCID 0000-0001-7189-7300 Marcella BellaniORCID 0000-0003-1727-5396 Marcello BorinORCID 0000-0003-1864-515X Marco ColizziORCID 0000-0001-6139-1920 Maria Gloria RossettiORCID 0000-0001-7843-8721 Mirella RuggeriORCID 0000-0002-9344-0528 Riccardo BortolettoORCID 0000-0002-0125-4112 Rosana ShuhamaORCID 0000-0001-7626-7543 Sarah TosatoORCID 0000-0002-9665-7538

Public evidence

17 connected articles

Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: A systematic review of diffusion-weighted MRI studies.2023 · PubMed Central Open Access Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.2023 · PubMed Central Open Access Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis.2022 · PubMed Central Open Access Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access Developing and Testing Molecular Markers in <i>Cannabis sativa</i> (Hemp) for Their Use in Variety and Dioecy Assessments.

Matched by exact identifiers only. Profile data: OpenAlex.

2021 · PubMed Central Open Access

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access

Sex and dependence related neuroanatomical differences in regular cannabis users: findings from the ENIGMA Addiction Working Group.2021 · PubMed Central Open Access

Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence.2020 · PubMed Central Open Access

Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior.2020 · PubMed Central Open Access

Cannabis and Cognition: Connecting the Dots towards the Understanding of the Relationship.2020 · Europe PMC

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis.2020 · PubMed Central Open Access

Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.2020 · Europe PMC

University of Verona - Medical Cannabis Research Engine